![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: GSTA2 |
Gene summary for GSTA2 |
![]() |
Gene information | Species | Human | Gene symbol | GSTA2 | Gene ID | 2939 |
Gene name | glutathione S-transferase alpha 2 | |
Gene Alias | GST2 | |
Cytomap | 6p12.2 | |
Gene Type | protein-coding | GO ID | GO:0006518 | UniProtAcc | A0A140VKE2 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2939 | GSTA2 | HCC1_Meng | Human | Liver | HCC | 3.89e-07 | -6.15e-03 | 0.0246 |
2939 | GSTA2 | HCC1 | Human | Liver | HCC | 6.04e-16 | 3.79e+00 | 0.5336 |
2939 | GSTA2 | HCC2 | Human | Liver | HCC | 2.31e-50 | 5.63e+00 | 0.5341 |
2939 | GSTA2 | Pt13.a | Human | Liver | HCC | 1.53e-115 | 1.43e+00 | 0.021 |
2939 | GSTA2 | Pt13.b | Human | Liver | HCC | 2.86e-38 | 5.16e-01 | 0.0251 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000679021 | Liver | HCC | sulfur compound metabolic process | 212/7958 | 339/18723 | 5.60e-14 | 3.39e-12 | 212 |
GO:000657521 | Liver | HCC | cellular modified amino acid metabolic process | 119/7958 | 188/18723 | 6.47e-09 | 1.67e-07 | 119 |
GO:000941022 | Liver | HCC | response to xenobiotic stimulus | 248/7958 | 462/18723 | 6.47e-07 | 1.02e-05 | 248 |
GO:000674911 | Liver | HCC | glutathione metabolic process | 44/7958 | 64/18723 | 1.95e-05 | 2.09e-04 | 44 |
GO:00714662 | Liver | HCC | cellular response to xenobiotic stimulus | 93/7958 | 177/18723 | 4.35e-03 | 1.89e-02 | 93 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0520842 | Liver | HCC | Chemical carcinogenesis - reactive oxygen species | 167/4020 | 223/8465 | 2.85e-17 | 1.91e-15 | 1.06e-15 | 167 |
hsa052258 | Liver | HCC | Hepatocellular carcinoma | 106/4020 | 168/8465 | 2.87e-05 | 1.85e-04 | 1.03e-04 | 106 |
hsa015242 | Liver | HCC | Platinum drug resistance | 52/4020 | 73/8465 | 3.14e-05 | 1.88e-04 | 1.04e-04 | 52 |
hsa0048022 | Liver | HCC | Glutathione metabolism | 42/4020 | 57/8465 | 5.00e-05 | 2.62e-04 | 1.46e-04 | 42 |
hsa0541842 | Liver | HCC | Fluid shear stress and atherosclerosis | 89/4020 | 139/8465 | 5.58e-05 | 2.88e-04 | 1.60e-04 | 89 |
hsa009832 | Liver | HCC | Drug metabolism - other enzymes | 54/4020 | 80/8465 | 2.25e-04 | 1.09e-03 | 6.08e-04 | 54 |
hsa0520852 | Liver | HCC | Chemical carcinogenesis - reactive oxygen species | 167/4020 | 223/8465 | 2.85e-17 | 1.91e-15 | 1.06e-15 | 167 |
hsa0522511 | Liver | HCC | Hepatocellular carcinoma | 106/4020 | 168/8465 | 2.87e-05 | 1.85e-04 | 1.03e-04 | 106 |
hsa015243 | Liver | HCC | Platinum drug resistance | 52/4020 | 73/8465 | 3.14e-05 | 1.88e-04 | 1.04e-04 | 52 |
hsa0048032 | Liver | HCC | Glutathione metabolism | 42/4020 | 57/8465 | 5.00e-05 | 2.62e-04 | 1.46e-04 | 42 |
hsa0541852 | Liver | HCC | Fluid shear stress and atherosclerosis | 89/4020 | 139/8465 | 5.58e-05 | 2.88e-04 | 1.60e-04 | 89 |
hsa009833 | Liver | HCC | Drug metabolism - other enzymes | 54/4020 | 80/8465 | 2.25e-04 | 1.09e-03 | 6.08e-04 | 54 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GSTA2 | SNV | Missense_Mutation | c.378N>T | p.Glu126Asp | p.E126D | P09210 | protein_coding | tolerated(0.53) | benign(0.001) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
GSTA2 | SNV | Missense_Mutation | novel | c.221N>G | p.Tyr74Cys | p.Y74C | P09210 | protein_coding | deleterious(0.02) | probably_damaging(1) | TCGA-D1-A175-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
GSTA2 | SNV | Missense_Mutation | novel | c.592N>A | p.Leu198Ile | p.L198I | P09210 | protein_coding | deleterious(0.01) | possibly_damaging(0.884) | TCGA-EO-A3AV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
GSTA2 | SNV | Missense_Mutation | c.331N>G | p.Phe111Val | p.F111V | P09210 | protein_coding | tolerated(0.07) | benign(0) | TCGA-KR-A7K8-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
GSTA2 | SNV | Missense_Mutation | rs752773504 | c.383C>T | p.Thr128Ile | p.T128I | P09210 | protein_coding | tolerated(0.06) | benign(0.015) | TCGA-86-8073-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
GSTA2 | SNV | Missense_Mutation | novel | c.645A>T | p.Glu215Asp | p.E215D | P09210 | protein_coding | tolerated(0.28) | benign(0.003) | TCGA-MN-A4N5-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
GSTA2 | SNV | Missense_Mutation | c.4N>A | p.Ala2Thr | p.A2T | P09210 | protein_coding | tolerated(0.13) | possibly_damaging(0.792) | TCGA-18-5592-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
GSTA2 | SNV | Missense_Mutation | novel | c.347N>G | p.Glu116Gly | p.E116G | P09210 | protein_coding | deleterious(0.03) | benign(0.055) | TCGA-21-1075-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
GSTA2 | SNV | Missense_Mutation | novel | c.316N>C | p.Ile106Leu | p.I106L | P09210 | protein_coding | tolerated(0.23) | benign(0.019) | TCGA-21-1079-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
GSTA2 | SNV | Missense_Mutation | c.289N>C | p.Glu97Gln | p.E97Q | P09210 | protein_coding | deleterious(0.01) | possibly_damaging(0.532) | TCGA-63-A5MH-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |